Interest and prospects of terbium-161 for Targeted Radionuclide Therapy: set-up in Bordeaux
Description
Targeted radionuclide therapy (TRT) of second generation (using somatostatin analogues or PSMA inhibitors radiolabeled with lutetium-177) is getting more and more importance in oncological therapeutic strategies. However, further optimizations are required to improve survival of patients with metastatic cancers. Terbium-161 (161Tb) demonstrates similar chemical properties with lutetium-177, with much higher proportion of low energy electrons emissions (Auger, Intern Conversion, Coster-Kronig), enabling increased dose-deposits in single tumor cells and micrometastases. Considering the rising interest of 161Tb in Europe, this work describes the preliminary steps before the set-up of this radionuclide in Bordeaux, in particular regulatory authorizations for detention and use, exclusion chromatography purification method of 161Tb (first with non-radioactive terbium) and then (radio)labeling. (author)
Abstract (French)
La radiotherapie interne vectorisee (RIV) de deuxieme generation (analogues de la somatostatine ou inhibiteurs du PSMA radiomarques au lutetium-177) prend de plus en plus de place dans les strategies therapeutiques en oncologie. Cependant des optimisations restent necessaires pour ameliorer la survie de ces patients metastatiques. Le terbium-161 (161Tb) presente des proprietes chimiques similaires au lutetium-177, tout en emettant une part plus importante d'electrons de faible energie (Auger, Conversion Interne, Coster-Kronig) responsables d'une meilleure irradiation de cellules tumorales isolees et micrometastases. En raison de l'interet croissant du 161Tb en Europe, ce travail decrit les etapes prealables necessaires a l'implantation de ce radio-isotope innovant a Bordeaux notamment les aspects reglementaires relatifs au regime d'autorisation de detention et utilisation, methodologie de purification du 161Tb par chromatographie d'exclusion (d'abord a l'aide du terbium non radioactif) et realisation de (radio)marquage. (auteur)
Files
Restricted
The record is publicly accessible, but files are restricted to users with access.
Additional details
Additional titles
- Original title (French)
- Interet et perspectives du Terbium-161 en radiotherapie interne vectorisee: mise en place a Bordeaux
- Augmented title (English)
- Targeted radionuclide therapy; Theragnostic; Radiopharmacy; Terbium-161; Chromatographic method; Auger emitter
Publishing Information
- Imprint Pagination
- 88 p.
- Report number
- FRNC-TH--16052
INIS
- Country of Publication
- France
- Country of Input or Organization
- France
- INIS RN
- 55093644
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE; S07: ISOTOPES AND RADIATION SOURCES;
- Resource subtype / Literary indicator
- Thesis
- Descriptors DEI
- AUGER ELECTRON SPECTROSCOPY; CHROMATOGRAPHY; DOSES; LABELLING; LUTETIUM 177; METASTASES; NEOPLASMS; OPTIMIZATION; PATIENTS; PURIFICATION; RADIATION DOSES; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; SOMATOSTATIN; TERBIUM 161; TUMOR CELLS
- Descriptors DEC
- ANIMAL CELLS; BETA DECAY RADIOISOTOPES; BETA-MINUS DECAY RADIOISOTOPES; DAYS LIVING RADIOISOTOPES; DISEASES; DOSES; DRUGS; ELECTRON SPECTROSCOPY; IMMUNOTHERAPY; INTERMEDIATE MASS NUCLEI; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; LABELLED COMPOUNDS; LUTETIUM ISOTOPES; MATERIALS; MEDICINE; NUCLEAR MEDICINE; NUCLEI; ODD-EVEN NUCLEI; RADIOACTIVE MATERIALS; RADIOISOTOPES; RADIOLOGY; RADIOTHERAPY; RARE EARTH NUCLEI; SEPARATION PROCESSES; SPECTROSCOPY; TERBIUM ISOTOPES; THERAPY
Optional Information
- Notes
- 52 refs.; Available from the INIS Liaison Officer for France, see the INIS website for current contact and E-mail addresses